mineral-nutrition.com

Israeli biotech companies Miletus and Yotvata Dairy are joining forces to advance Miletus’s Imilac product as a replacement for antibiotics in milk dairy products.Under the agreement, Yotvata will invest money to improve management systems of dairy farms. Financial details were not disclosed, but the agreement includes the prototype of a “cutting-edge dairy farm management system,” that will serve as a model for operate commercial dairy without antibiotics. The investment comes after Miletus completed a clinical trial where the product “demonstrated its effectiveness” in increasing milk quantity and yield. The trial involved more than 500 cows at seven large Israeli dairy farms, the company said. “Dairy companies around the world are starting to recognize that Mileutis’ innovative solutions are poised to propel the industry forward towards a more sustainable future, benefiting ferro f tab cmiconsumers, dairy farmers and animals alike,” David Javier Iscovich, CEO and co-founder of Mileutis, said in a statement. “The agreement with Yotvata is anolow dose ferrous sulfatether milestone towards our vision of leading the dairy industry into a sustainable future, which is facing significant challenges.”Antibiotics in milk and dairy products are used for disease prevention, growth promotion and treating mastitis. However, they have also been found to cause problems for consumers and milk processors, according to The National Institutes of Health.These include cancer and hypersensitivity reactions, along with the development of antibiotic thorne zinc bisglycinateresistance. Miletus said its products reduce greenhouseferrous fumarate trade name gas emissions by increasing milk yield per cow. Ninety percent of the largest dairy processxymogen vitamining companies have set a goal to become carbon neutral by 2050, according to the company. Miletus added that the extra milk produced from Imilac helps dairy farmers’ productivity and profitability.